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1. INTRODUCTION 
1.1. ORAL DRUG DELIVERY SYSTEM  
Oral drug delivery has been known for decades as the most widely utilized route of 
administration among all the routes that have been explored for the systemic delivery of 
drug via various pharmaceutical products of different dosage forms. The reason that the 
oral route achieved such popularity may be attributed to its ease of administration as well 
as the traditional belief that by oral administration the drug is well absorbed as the food 
staffs ingested daily. In fact the development of pharmaceutical products for oral 
delivery, irrespective of physical form involves varying extents of optimization of dosage 
form within the inherent constraints of GI physiology. Therefore a fundamental 
understanding of various disciplines, including GI physiology Pharmacokinetics, 
pharmacodynamics and formulation design are essential to achieve a systemic approach 
to the successful development of an oral dosage form. The more sophisticated a delivery 
system the greater is the complexity of these various disciplines involved in the design 
and optimization of the system. In any case the scientific development of oral drug 
delivery system consists of a basic understanding of the following there aspects1. 
a) Physicochemical, pharmacokinetic and pharmacodynamic 
characteristics of the drug. 
b) The anatomic and physiologic characteristic of the GIT. 
c) Physicochemical characteristic and the drug delivery mode of the 
dosage form to be designed. 
          Many patients have difficulty swallowing tablets and hard gelatin capsules and 
consequently do not take medications as prescribed. It is estimated that 50% of the 
population is affected by this problem which results in a high incidence of non-
compliance and in effective therapy. It has been reported that dysphagia (difficulty in 
swallowing) is common among all age groups and more specific with pediatric, geriatric 
population along with institutionalized patients and patients with nausea. Because of the 
increase in the average human life span and the decline, with age, in swallowing ability, 
oral tablet administration to patients is a significant problem and has become the object of 
public attention. The problem can be resolved by the creation of rapidly dispersing or 
dissolving oral forms, which do not require water to aid swallowing. The dosage forms 
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are placed in the mouth, allowed to disperse or dissolve in the saliva, and then are 
swallowed in the normal way. 
        The orally disintegrating tablets are also caused as oro dispersible tablet, quick 
disintegrating tablets, fast disintegrating tablets, porous tablets rapimelts. However of all 
the above terms, United States pharmacopeia (USP) approved these dosage forms as 
ODTs. Recently, European pharmacopeia has used the term “orodispersible tablet” for 
tablets that disperse readily and within three minutes before swallowing. United States 
food and drug administration (FDA) defined ODT as “A solid dosage form containing 
medicinal substance or active ingredient which disintegrates rapidly usually within a 
matter of seconds when placed upon the tongue”. The disintegration times for ODTs 
generally range from several seconds to about a minute. 
         Mouth dissolving tablets are most widely used dosage form because of it’s 
convenience in terms of self-administration, compactness and ease in manufacturing. Fast 
disintegrating tablets rapidly gaining acceptance as an important new drug technology. 
These dosage forms dissolve or disintegrate in oral cavity within a minute even without 
the need of water or chewing. 
1.1.1 MOUTH  
              The mouth also referred to as the oral (or) buccal cavity is formed by the cheeks, 
hard and soft palates and tongue. The cheek from the lateral walls of the oral cavity. They  
are covered externally by skin and internally by a mucous membrane ,which consist of 
nonkeratinized stratified squamous epithelium buccinators muscles and connective tissue 
lie cheeks. The anterior portions of the cheeks end at the lips. The lips (or) labia are 
freshly folds surrounding the opening of the mouth. They contain the orbicularisoris 
muscle and are covered externally by skin and internally by a mucous membrane. The 
inner surface of each lip is attached to this corresponding gum. By a midline fold of 
mucous membrane called the labial frenulum. During chewing contraction of the 
buccinators muscles in the cheeks and orbicularisoris muscle in the lips helps keep food 
between the upper and lower teeth. These muscles also consist in speech. 
              The oral vestibule of the oral cavity is a space bounded externally by the cheeks 
and lips and internally by the gums and teeth. The oral cavity proper is a space that 
extends from the gums and teeth to the opening between the oral cavity and the 
CHAPTER-1                                                                                         INTRODUCTION 
 
J.K.K.NATTRAJA COLLEGE OF PHARMACY Page 3 
 
oropharynx. The palate is a wall (or) septum that separates the oral cavity from the nasal 
cavity, forming the loof of the mouth. This important structure makes it possible to chew 
and breath at the same time. The hard palate the anterior portion of the loof of the mouth 
is formed by maxillae and palatine bones and is covered by a mucous membrane it forms 
a bony partition between the oral and nasal cavity. The soft palate, which forms the 
posterior portion of loof of the mouth is an arch-shaped muscular partition between the 
oropharynx and nasopharynx that is lined with mucous memberane. 
Figure 1: Drug Release from tablets 
 
 
1.2. DESIRED CRITERIA FOR MOUTH DISSOLVING DRUG DELIVERY 
SYSTEM 
The tablet should: 
 Not require water to swallow, but is should dissolve (or) disintegrate in the mouth 
in matter of seconds. 
 Be compatible with taste masking. 
 Be portable with taste masking. 
 Have a pleasing mouth feel. 
 Leave minimal (or) no residue in the mouth after oral administration. 
 Exhibit low sensitivity to environmental conditions as humidity and temperature. 
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 Allow the manufacture of tablet using conventional processing and packaging 
equipment at low cost, 
 Allow the manufacture of tablet using conventional processing and packaging 
equipment at low cost. 
1.3. SALIENT FEATURES OF MOUTH DISSOLVING TABLET 
 Ease of administration to patient who refuses to swallow tablets, such as 
pediatric, geriatric and psychiatric patients. 
 No need of water to swallow the dosage form, which is highly convenient feature 
for patients who are travelling and do not have immediate access to water. 
 Rapid dissolution and absorption of drug which will produce quick onset of 
action. 
 Some drugs are absorbed from the mouth, pharynx, and esophagus as the saliva 
passes down into the stomach in such cases bio-availability of drugs in increased. 
 Pre-gastric absorption can result in improved bio-availability and as a result of 
reduced dosage. Improve clinical performance through a reduction of unwanted 
effects. 
1.4. ADVANTAGES OF MOUTH DISSOLVING TABLETS 
 Improved patient compliance. 
 Rapid onset of action and may offer an improved bio-availability. 
 Patient having difficulty in swallowing tablet can easily administer this type of 
dosage form. 
 Useful fro-pediatric, geriatric and psychiatric patients. 
 Suitable during travelling where water is may not be available. 
 Gives accurate dosing as compared to liquids. 
 Good chemical stability. 
 Free of need of measuring, an essential drawback in liquids. 
1.5. LIMITATION OF MOUTH DISSOLVING TABLETS 
 The tablets usually have insufficient mechanical strength. Hence careful handling 
is required. 
 The tablets may leave unpleasant taste and for grittiness in mouth if not 
formulated properly. 
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  These tablets usually have low hardness, so they are friable or brittle. They are 
difficult to handle. 
 And require specialized packaging. 
 
1.6. SIGNIFICANCE OF DISSOLVING TABLETS 
 They provide good stability, accurate dosing, easy manufacturing small packaging 
size and easy to handle by patients. 
 No risk of obstruction of dosage from, which is beneficial for travelling patients 
who do not have access to water. 
 Easy to administer for pediatric, geriatric and institutionalized patients. 
(especially for mentally retarded and psychiatric patients) 
 Rapid disintegration of the tablet results in quick dissolution and rapid absorption 
which provide rapid onset of action. 
 Medications as “bitter pill” has changed by excellent mouth feel property 
produced by the use of flavors and sweeteners in mouth dissolving tablets. 
 Bioavailability of drugs that are absorbed from mouth, pharynx and oesophagus is 
increased. 
 Pregastric absorption of drugs avoids hepatic metabolism, which reduces the dose 
and increase the bioavailability. 
 Improved taste and not produce any residue in the mouth. 
 Insensitive to environmental conditions. 
1.7. FORMULATION ASPECTS IN DEVELOPING MDT 
            Mouth disintegrating tablets are formulated by utilizing several process, which 
differ in their methodologies and the MDTs formed vary in various properties such as, 
 Mechanical strength of tablets 
 Taste and mouth feel 
 Swallowability 
 Drug dissolution in saliva. 
 Bioavailability 
 Stability 
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1.7.1. VARIOUS APPROACHES FOR MOUTH DISSOLVING TABLETS 
        The property of mouth dissolving tablets is attributable to a quick intake of water 
in to the tablet matrix resulting rapid disintegration and instantaneous dissolution of the 
tablets. 
• Maximizing the pore structure of tablet matrix. 
• Using highly water soluble excipients in the formulation. 
• Incorporating appropriate disintegrating agents. 
Disintegrates act by any one of the following mechanisms, 
 Capillary action 
 High swell ability 
 Release of gas by chemical reaction. 
1.7.2.METHODS FOR THE FORMULATION OF MOUTH DISSOLVING 
TABLETS 
             Various processes employed in formulating MDTs are described below. 
A.PATENTED TECHNOLOGIES 
1. ZYDUS TECHNOLOGY 
      This technology involves physical trapping of drug in a matrix composed of a 
saccharide and a polymer .The polymer generally used are partially hydrolyzed gelatin, 
hydrolyzed dextran, dextrin, alginate, polyvinyl alcohol, polyvinyl pyrrolidone, acacia 
and these mixtures. The methodology involves solution or dispersion of components is 
prepared and filled in to blister cavities, which are frozen in a liquid nitrogen 
environment. The frozen solvent is removed or sublimed to produce porous wafers. 
Peelable backing is used to pack zydis units. These formulations are sensitive to moisture 
and may degrade at humidity greater than 65% zydis is patented by R.P. Scherer. 
2. LYOC 
         Oil in water emulsion is prepared and placed directly in to blister cavities 
followed by freeze drying. Non homogeneity during freeze drying is avoided by 
incorporating inert filler to increase the viscosity finally the sedimentation. The 
methodology is patented by pharmalyoc. 
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3. QUICK SOLV 
        Methodology includes dissolving matrix components in water and the solution or 
dispersion is frozen. Then dry the matrix by removing water using an excess alcohol 
(solvent extraction). The product formed has uniform porosity and adequate strength for 
handling. This technology patented by Jassen Pharmaceuticals. 
 
4. NANOCRYSTAL TECHNOLOGY 
        Nano crystal technology includes lyophilization of colloidal dispersion of drug 
and water soluble ingredients filled into blister pockets. This method avoid 
manufacturing process such as granulation, blending and tableting. This method is 
advantageous for highly potent and hazards drugs, manufacturing losses are negligible 
and the process is small quantities of drugs. This methodology is patented by Elanking of 
Prussia. 
5. FLASH TAB TECHNOLOGY 
          This technology includes granulation of excipients by wet granulation method and 
follow by compressing in to tablets excipients used in this technology are of two types. 
Disintegrating agents include reticulated polyvinyl pyrolidone or carboxy methyl 
cellulose, starch, modified starch, microcrystalline cellulose, carboxy methylated starch, 
etc. tablets formed have satisfactory physical resistance. Disintegration time is within 1 
minute. This methodology patented by Ethypharm, France. 
6. ORASOLV TECNOLOGY  
           This includes use of effervescent disintegrating agents compressed with low 
pressure to produce MDTs. The evaluation of carbon dioxide from the tablet produces 
fizzing sensation, which is a positive organoleptic properties. Concentration of 
effervescent mixed usually employed is 20-25%of tablet weight .as the tablets prepared at 
low compression force, they are soft and fragile in nature. This is initiated to develop 
paksolv, a special packaging to protect tablets during storage and transport. Paksolv is 
dome-shaped blister package, which prevents vertical movements of tablets in the 
depression. This offers moisture, light and child resistance packing. 
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7. DURASOLV TECNOLOGY    
            This methodology utilized conventional tableting equipment and tablets are 
formulated by using drug non-direct compression fillers and lubricants. Non direct 
compression fillers are dextrose mannitol, sorbitol, lactose, and sucrose which have 
advantages of quick dissolution avoid gritty structure (which is generally present in direct 
compressible sugar)The tablets formed are strong and can be packed in conventional 
packing in bottles and blisters. Nondirect compressible fillers generally used in the range 
of 60-95%,lubricants in 1-2.5%.this technology patented by CIMA labs. Durasolv 
products include Nulev (hyoscyaminesulphate),Zoming ZMT(Zolmitraptan). 
8. WOW TAB TECNOLOGY 
 This technology utilizes conventional granulation and tableting methods to 
produce MDTs employing low-and high moldability saccharides. WOW means with out 
water. Low moldabilty saccharides are lactose, mannitol, glucose, sucrose and xylitol. 
High moldability saccharides are maltose, maltitol, sorbitol and oligosaccharides. When 
these  two type saccharides used alone tablets obtained do not have desired properties of 
rapid disintegration and hardness, so combination are used. This technology involves 
granulation of low-moldable saccharieds as a binder and compressing in to tablets 
followed by moisture treatment. So the tablets formed showed adequate hardness and  
rapid disintegration .this technology patented by Yamanouchi. WOW tab product include 
Benadryl allergy and sinus fast melt (OTC). 
9. DISPERSIBLE TABLET TECNOLOGY 
It offers development of MDT improved dissolution rate by incorporating 8-10% 
of organic acid and disintegrating agents. disintegrating agents facilitates rapid swelling 
and good  wetting results in quick disintegration. Disintagrants include starch, modified 
starches, microcrystalline cellulose, alginic acid, cross linked sodium carboxy methyl 
cellulose and cyclodextrines. Combilnation of disintegarants improved disintegration 
usally less than 1 minutes. The methodology patented lek, Yugoslavia. 
10. PHARMA BURST TECNOLOGY   
It utilize co proceed exicipients to develop MDT which dissolves within 30-40 
seconds. The technology involves dry blending of drugs, flavor and lubricant followed by 
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compression in to tablets. The tablets obtained have sufficient strenghth so they can be 
packed in blister packs and bottles. This technology patened by SPI pharma, new castle. 
11. FROSTA TECHNOLOGY  
            It utilizes the concept of formulating plastic granules and compressing at low 
pressure to produce strong tablets with high porosity. Plastic granules composed of 
porous and plastics material, water penetration enhancer and binder. The process involves 
mixing the porous plastic material with water penetration enhancer and followed by 
granulating with binder. The product showed excellent hardness and rapid disintegration 
within 15-30 seconds. This methodology patented by Akina. 
12. ORAQUICK 
        It utilize taste masking microspheres technology called as micro mask, which 
provides superior mouth feel, significant mechanical strength and quick disintegration 
and dissolution of the products. This process involves preparation of micro particles in 
the form of matrix that protects the drug which can be compressed with sufficient 
mechanical strength. Low heat of production in this process make it suitable for heat 
sensitive drug. The products formed dissolves within few seconds. The methodology 
patented by K.V Pharmaceuticals. 
13. ZIPLETS OR ADVATAB 
      It utilize water insoluble gradients combined one are more effective disintegrants 
to produce MDT s with improved mechanical strength and optimum disintegration time 
at low compression force. Advantage of the method include high drug loading, formation 
of coated particles and does not require special packaging. This technology patented by 
pessano con Bornago. 
14. FLASHDOSE  
            The flash dose tablets consists of self binding shear form matrix termed as floss. 
Shear form matrices are prepared by flash heat processing. This technology patented by 
Fluzisz. Egibuprofen melt in mouth tablets. 
B.CONVENTIONAL METHODS     
1. LYOPHILIZATION OR FREEZE-DRYING 
           Lyophilization is a process which includes removal of a solvent from a frozen 
suspension of drug with structure forming additives. Freeze drying of a drug along with 
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additives imparts glossy amorphous structure resulting in highly porous and light weight 
product. The resulting  tablet has rapid disintegration and dissolution when placed on a 
tongue and the freeze dried leutin dissolves instantly to release the drug. MDT s formed 
by lyophilization have some demerits like low mechanical strength, poor stability at 
higher temperature and humidity. Use of expensive equipment for freeze drying is 
another demerits of the process. 
2. MOULDING 
          Molding process include moistening, dissolving or dispersing the drug with a 
solvent then molding the moist mixer in to tablets(compression molding with a low 
pressure  than conventional tablet compression )evaporating the solvent from drug 
solution, or suspension at ambient pressure respectively. The molded tablets formed by 
compression molding are air dried. As the compression force employed is lower than 
conventional tablet, the molded tablet results in highly porous structure, which increase 
the disintegration and dissolution of the product. To further improve the dissolution rate 
of the product powder mixer should be sieved through very fine screen. This process is 
applied usually with soluble ingredients (saccharides) which offer improved mouth feel 
and disintegration of tablets. Some of the demerits observed are the tablet formed by this 
process shows low mechanical strength, which results in erosion and breakage during 
handling. 
3. COTTON CANDY PROCESS 
         Cotton candy process involves formation of matrix of polysaccharides or 
saccharides by simultaneous action of flash melting and spinning. The matrix formed is 
partially recrystallized to have improved flow properties and compressability. This candy 
floss matrix is then milled and blended with active ingredients and excipients and 
subsequently compressed to MDTs. This process is so named because it utilizes a unique 
spinning mechanism to produce floss-like crystalline structure, which mimic cotton 
candy. The main merits of this method are the process can accommodate high doses of 
drug and offers improved mechanical strength. The main demerit is the use of high 
process temperature. 
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4. SPRAY DRYING 
          In this method MDTs formulated by using hydrolyzed / unhydrolyzed gelatin as 
supporting agent for matrix, mannitol as bulking agent and sodium starch glycolate or 
croscarmellose sodium as disintegrating agent. Disintegration and dissolution were 
further improved by adding effervescent components.ie citric acid (an acid) and sodium 
bicarbonate (an alkali). The formulation was spray dried to yield a porous powder. The 
products formed are highly porous fine powders and are disintegrated in<20 seconds. 
Allen et al utilized this method for preparing MDTs. 
5. MASS EXTRUSION 
          It involves softening the active blend using the solvent mixture of water soluble 
polyethylene glycol and methanol and subsequent expulsion of softened mass through the 
extruder or syringe to get a cylinder of the product in to even segments using heated 
blade to forms tablets. (yadav A.V et al,2010) 
6. COMPACTION MELT GRANULATION 
        The method involves incorporation of hydrophilic waxy binder (super poly state.) 
PEG -6-sterate. Super poly state is a waxy material with an M.P of 33-37c. and an 
hydrophilic lipophilic balance of 9. It act as binder, increase the physical resistance of 
tablets and it helps the disintegration of tablets as it melt in the mouth and solubilizes 
rapidly leaving no residue. Super poly state incorporated in the formula by melt 
granulation method, where granules are formed by the molten form of the material. eg 
crystallized paracetamol was used as model drug and in addition mannitol added as water 
soluble excipient and cross carmellose sodium as disintegrating agents. Abdlbary et al 
prepared MDT by this method. 
7. PHASE TRANSITION PROCESS 
        Kuno et al investigated disintegration of MDTs are formulated by sugar alcohols 
using erythriol (M.P 122C), xylitol (m.p 93-95), trehalose (97c) and mannitol (166c). 
This method involves compressing a powder containing two sugar alcohols with high and 
low-melting points and subsequent heating at temperature between their melting points. 
Before heating process the tablet do not have sufficient hardness because of low 
compatibility. The tablet hardness was increased after heating process, due to the increase 
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of interparticular bonds or bonding surface area in tablets induced by phase transition of 
low melting point sugar alcohols. 
8. SUBLIMATION  
        The method involves addition of volatile salt to the tableting components, mixing 
and volatilizing the volatile salt creates pores  in the tablets come in contact with saliva. 
Camphor, naphthalene, urea, ammonium bi carbonate etc., can be used to prepare porous 
tablets of good mechanical strength. koizumi et al used mannitol as diluents and camphor 
as volatile material to prepare porous compressed tablet. The tablets were subjected to 
vaccum at 80 c for 30 minutes to eliminate camphor and thus form the pores in the tablet. 
The tablet formed have highly porous matrix which is the key factor for rapid 
disintegration. 
C.OTHER METHODS   
         Other methods includes dry granulation, wet granulation and direct compression 
methods. The important components used in these methods are super disintegrants.  
1. DRY GRANULATION   
          In this technique there is no use of liquids. The process involves the formation of 
slugs. Then slugs are screened are milled to produce granules. The granules formed are 
then compressed to form tablet. 
2. WET GRANULATION  
          The process involves addition of liquids to a powder in a vessel equipped with any 
type of agitation that will produce agglomeration or granules. These granules after drying 
are compressed to form tablets. This method have more operational manipulation and is 
more time consuming than other methods. this  method is not suitable for drugs which ass 
thermo labile or hydrolysable by presence of water in the liquid binder. 
3. DIRECT COMPRESSION 
          In direct compression method, of powder blends of active ingredients and suitable 
excipients, which will flow uniformly in the die cavity and formed a film compact 
(Banker G.S et al 1987).direct compression method are very popular because it reduse 
the number of steps involved and the materials required. 
Advantages       
1. Easiest method to manufacture fast dissolving tablets. 
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2. Low manufacturing cost. 
3. Use of conventional equipment and commonly available excipients. 
4. High quality finished product. 
Figure 2: Flow sheet of direct compression 
                       DIRECT COMPRESSION METHOD 
  Drug                                                                        
  Diluent 
  Glidant                                                 Mixing 
  Disintegrant   
                                                
                
Lubricant                                                  Mixing  
                                      
 
                                       Compression mix 
                                                                         
                        File Die, Compress Tablet, Eject Tablet  
                                                           
                     Metal check, De dusting, Coating Packaging  
 
Super Disintegrants in Immediate Release Tablets 
Super-disintegrants are effective at low concentration and have greater disintegrating 
efficiency and they are effective intra-granularly as well as extra-granularly. But have 
one drawback that it is hygroscopic therefore not used with moisture sensitive drugs. 
These super-disintegrants act by swelling and due to swelling pressure exerted in the 
outer direction or radial direction, it causes tablet to burst or accelerate the absorption of 
water leading to an enormous increase in the volume of granules to promote 
disintegration is shown in Fig 2.  
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Fig 3: Mechanisms of Super-disintegrant swelling 
 
Granules with  super disintegrant                         Swelling of granules 
             in aqueous medium                                             due to super-disintegrant 
 
Table 1: LIST OF SUPERDISINTEGRANTS 
SUPERDISINTEGRANTS TYPE 
MECHANISM OF 
ACTION 
SPECIAL COMMENTS 
Croscarmellose 
Ac-Di-Sol 
Nymce ZSX 
Primellose 
Solutab 
Vivasol 
 
Crosslinked 
Cellulose 
Swells 4-8 
folds in < 10 
seconds 
 
Swelling and 
wicking both. 
Swells in two 
dimensions. 
 
Direct compression or 
Granulation 
Starch free 
Crospovidone 
Crospovidon M 
Kollidon 
Polyplasdone 
 
 
Crosslinked 
PVP 
Swells very 
little and returns 
to original size 
after 
compression 
but act by 
capillary action 
Water insoluble and 
spongy in nature so get 
porous tablet 
Sodium starch glycolate 
Explotab 
Primogel 
Crosslinked 
Starch 
Swells 7-12 
folds in 
<30 seconds 
Swells in three 
dimensions and high 
level serve as sustain 
release matrix 
Alginic acid NF 
Satialgine 
Crosslinked 
alginic acid 
 
 
Rapid swelling 
in aqueous 
medium or 
wicking action 
Promote 
disintegration in both 
dry or wet granulation 
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Table 2: PARAMETERS INFLUENCING THE SWELLING BEHAVIOUR OF 
SUPERDISINTEGRANTS (6-8) 
EFFECT OF EXCIPIENTS USED IN THE FORMULATION: 
a) Effect of fillers: 
The solubility and compression characteristics of fillers affect both rate and 
mechanism of disintegration of tablet. If soluble fillers are used then it may cause 
increase in viscosity of the penetrating fluid which tends to reduce effectiveness of 
strongly swelling disintegrating agents and as they are water soluble, they are likely to 
dissolve rather than disintegrate. Insoluble diluents produce rapid disintegration with 
adequate amount of disintegrants. Tablets made with spray dried lactose (water soluble 
filler) disintegrate more slowly due to its amorphous character and has no solid planes on 
which the disintegrating forces can be exerted than the tablet made with crystalline 
lactose monohydrate. 
 
 
PARAMETERS EFFECTS 
Amount of superdisintegrant A minimum amount of superdisintegrant is necessary for the 
development of sufficient swelling to outer membrane 
Additives ( binders ) 
 
Polymeric binders can reduce swelling pressure by spacial 
separation of superdisintegrant particles or competition for 
free water 
Ionic strength of the 
medium 
Competition of the ions for free water 
pH values Swelling can be influenced for the superdisintegrants with 
ionizable groups(e.g:carboxylic groups in croscarmellose ) 
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b) Effect of binder: 
         As binding capacity of the binder increases, disintegrating time of tablet increases 
and this counteract the rapid disintegration. Even the concentration of the binder can also 
affect the disintegration time of tablet. 
c) Effect of lubricants: 
Mostly lubricants are hydrophobic and they are usually used in smaller size than 
any other ingredient in the tablet formulation. When the mixture is mixed, lubricant 
particles may adhere to the surface of the other particles. This hydrophobic coating 
inhibits the wetting and consequently tablet disintegration. Lubricant has a strong 
negative effect on the water uptake if tablet contains no disintegrants or even high 
concentration of slightly swelling disintegrants. On the contrary, the disintegration time is 
hardly affected if there is some strongly swelling disintegrant present in the tablet.    
Methods of addition of Disintegrants: 
Disintegrating agent can be added either prior to granulation (intragranular) or 
prior to compression (after granulation i.e. extragranular) or at both processing steps.  
Extragranular fraction of disintegrant (usually, 50% of total disintegrant requires) 
facilitates breakup of tablets to granules and the intragranular addition of disintegrants 
produces further erosion of the granules to fine particles. 
 
1.5 Tablet Compression  
 After the preparation of granules (in case of wet granulation) or sized slugs (in 
case of dry granulation) or mixing of ingredients (in case of direct compression), they are 
compressed to get final product. The compression is done either by single punch machine 
(stamping press) or by multi station machine (rotary press). 
The tablet press is a high-speed mechanical device. It 'squeezes' the ingredients 
into the required tablet shape with extreme precision. It can make the tablet in many 
shapes, although they are usually round or oval. Also, it can press the name of the 
manufacturer or the product on the top of the tablet. Each tablet is made by pressing the 
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granules inside a die, made up of hardened steel. The die is a disc shape with a hole cut 
through its centre. The powder is compressed in the centre of the die by two hardened 
steel punches that fit into the top and bottom of the die. 
             The punches and dies are fixed to a turret that spins round. As it spins, the 
punches are driven together by two fixed cams - an upper cam and lower cam. The top of 
the upper punch (the punch head) sits on the upper cam edge .The bottom of the lower 
punch sits on the lower cam edge .The shapes of the two cams determine the sequence of 
movements of the two punches. This sequence is repeated over and over because the 
turret is spinning round.  
The force exerted on the ingredients in the dies is very carefully controlled. This ensures 
that each tablet is perfectly formed. Because of the high speeds, they need very 
sophisticated lubrication systems. The lubricating oil is recycled and filtered to ensure a 
continuous supply. 
Common stages occurring during compression: 
Stage 1: Upper punch is withdrawn from the die by the upper cam. Lower punch is low 
in the die so powder falls in through the hole and fills the die. 
Stage 2: Lower punch moves up to adjust the powder weight-it raises and expels some 
powder. 
Stage 3: Upper punch is driven into the die by upper cam and lower punch is raised by 
low cam . Both punch heads pass between heavy rollers to compress the powder. 
Stage 4: Upper punch is withdrawn by the upper cam and lower punch is pushed up and 
expels the tablet.  Tablet is removed from the die surface by surface plate. 
1.3.2. FACTORS AFFECTING THE DRUG RELEASE:  
                Factors of in-vivo important that can affect and hence absorption can be 
categorized into 2 classes. 
1. Physicochemical properties of drug and 
2. Dosage form factors. 
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              The various physicochemical properties of drug that effect drug dissolution and 
its rate are – solubility, particle size, polymorphism, salt form, pseudo-polymorphism, 
complexation, wettability, etc. 
 Dosage form factors include manufacturing process and excipients incorporated 
in them. Several manufacturing processes influence drug dissolution form. Processes of 
such importance  in manufacture of tablets are: 
1. method of granulation and  
2. Compression force. 
 The excipients such as binders, lubricants, disintegrants., etc influence the drug 
dissolution. 
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2. LITERATURE REVIEW 
Nyol Sandeep., et. al, studied of all dosage forms tablet is the most popular dosage form 
existing today because of its convenience of self administration, compactness and easy 
manufacturing, sometimes immediate onset of action is required than conventional 
therapy in many cases. So that to overcome these drawbacks, immediate release dosage 
form has emerged as alternative oral dosage forms. Immediate drug release dosage forms 
disintegrate rapidly after administration with enhanced rate of dissolution. The basic 
approach used in development tablets is the use of superdisintegrants like Cross linked 
Polyvinylpyrrolidone or crospovidone (Polyplasdone), Sodium starch glycolate 
(Primogel, Explotab), carboxymethylcellulose (Croscarmellose) etc. The development of 
immediate release therapy also provides an opportunity for a line extension in the 
marketplace, a wide range of drugs e.g., neuroleptics, cardiovascular drugs, analgesics, 
antihistamines and other drugs can be considered candidates for this dosage form.  
Mayank Bansal., et. al,  studied on an immediate release tablet of Zaltoprofen for the 
treatment of pain and inflammation, by using superdisintgrant such as Croscarmellose 
sodium and different grades of microcrystalline cellulose. Immediate release tablets of 
Zaltoprofen were prepared by direct compression method using superdisintgrant such as 
Croscarmellose sodium and different grades of microcrystalline cellulose in different 
ratios. Sodium starch glycolate was added to aid disintegration. Tablets were found to be 
satisfactory when evaluated for thickness, hardness, friability, weight uniformity, drug 
content, disintegration time and in vitro drug release. The tablet disintegration time was 
less than one minute for all the tablet formulations. The in vitro drug release in optimized 
formulation F14 was found to be 98.89 % in 45 min. 
BK Garg., et. al,  has carried the study to develop and evaluate a pulsatile drug delivery 
system consisting of cores coated with two layers of swelling and rupturable coatings was 
prepared and evaluated as pulsatile drug delivery system. Cores containing Rosuvastatin 
calcium as model drug were prepared by direct compression of different ratios of spray-
dried lactose and microcrystalline cellulose and were then coated sequentially with an 
inner swelling layer containing a superdisintegrant (croscarmellose sodium) and an outer 
rupturable layer of ethylcellulose. The effect of level of swelling layer was investigated. 
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Rupture and dissolution tests were performed using the USP XXIV paddle method at 50 
rpm in 0.1 N HCl. The lag time of the pulsatile release tablets decreased with increasing 
levels of swelling layer. Increasing levels of the ethylcellulose coating retarded the water 
uptake and thus prolonged the lag time.  
Jigar A Patel., et. al, studied on developing immediate release tablet is accomplished by 
using a suitable diluents and super-disintegrants. Faster disintegration of the tablet 
administrated orally minimizes absorption time and improves its bioavailability in less 
time. Immediate Release tablet of Antibiotic drug is formulated using dry granulation 
using super disintegrant croscarmellose sodium. One of the important studies included in 
the present investigation is of study on process parameter effect on performance of the 
Immediate Release tablets. The effect of selected process parameters on critical 
properties of immediate release (IR) tablets were studied, like effect of disintegration 
time, friability, dissolution profile. 
Ujwala R. Bagmar., et. al, carried a research work is to develop immediate release 
tablets of Fexofenadine hydrochloride. The rate of dissolution and bioavailability of the 
Fexofenadine HCL may be increased by using superdisintegrant in its immediate release 
tablets. Direct compression method was adapted to prepare the tablets by using lactose, 
microcrystalline cellulose as filler, crospovidone and sodium starch glycolate as 
superdisintegrant in different concentration (2-8%). Disintegration time decreased with 
increase in the level of crospovidone. Whereas, disintegration time increased with 
increase in the level of sodium starch glycolate. The results indicate that the selected 
batch of tablet formulation containing crospovidone provides DT between 3-6 minutes 
with sufficient crushing strength and accepted friability. It was concluded that immediate 
release tablet for Fexofenadine hydrochloride can be formulated for fast treatment of 
allergic rhinitis.  
Hitesh P. Patel., et al studied on The aim of this study was to compare the disintegrants 
efficiency of the three superdisintegrants (Ac-Di-Sol, Crospovidone, Sodium starch 
glycolate) by formulating Zolpidem Tartrate immediate release tablets by direct 
compression method. Disintegration efficiency of powder disintegrants compared by 
swelling & hydration capacity of disintegrants. While efficiency of disintegrants in 
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tablets compared by various test like disintegration time, dissolution test, wetting time & 
maximal water uptake study of Zolpidem Tartrate immediate release tablets. The rapid 
disintegration observed for the Ac-Di-Sol containing tablets, comparing three classes of 
superdisintegrants represented by Ac-Di-Sol, Crospovidone, Sodium starch glycolate 
(SSG). The disintegration efficiency was found in following decreasing order Ac-Di-Sol, 
Crospovidone and Sodium starch glycolate. 
Sravani Shilpa. K., et al investigated is undertaken with an aim to develop 
pharmaceutically equivalent, stable, cost effective and quality improved formulation of 
clopidogrel bisulfate immediate release tablets The current study involves preparation 
and evaluation of clopidogrel bisulfate tablets, comparison of dissolution rate of 
optimized formula with innovator’s product and estimation of similarity and difference 
factors.The similarity and dissimilarity factor obtained for clopidogrel bisulfate was 
found to be within the standards.The formulation F-6 exhibited similar release profile to 
that of innovators product at each time point. Hence, F-6 was considered as the best 
formulation.  
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3. AIM AND OBJECTIVES 
 
 The present study is planned to develop Sumatriptan Succinate into 
immediate release tablets by direct compression Method. 
 Sumatriptan Succinate, is a synthetic drug belonging to the triptan class. 
Structurally, it is an analog of the naturally occurring neuro-active alkaloids 
dimethyltryptamine (DMT), bufotenine, and 5-methoxy-dimethyltryptamine, 
with an N-methyl sulfonamidomethyl- group at position C-5 on the indole 
ring. 
 Sumatriptan Succinate, is a medication used for the treatment of migraine and 
cluster headaches. 
 The poor hydrophilicity of the drug results in variable dissolution rate and 
poor bioavailability.  In this study, we tried to prepare Sumatriptan MDT by 
using various types of disintegrants by direct compression method. 
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4. PLAN OF WORK 
 Preformulation Studies 
 Solubility 
 Drug and excipient compatibility studies by FTIR     
 Bulk density 
 True density  
 Carr’s index  
 Hausner’s ratio 
 Angle of repose 
 Formulation development  
 Evaluation Studies 
• Hardness 
• Friability 
• Thickness 
• Weight variation 
• Content uniformity 
• Invitro Dissolution study 
• Stability Studies 
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5. DISEASE PROFILE 
A migraine is a primary headache disorder characterized by recurrent headaches 
that are moderate to severe. Typically, the headaches affect one half of the head, are 
pulsating in nature, and last from two to 72 hours. Associated symptoms may include 
nausea, vomiting, and sensitivity to light, sound, or smell. The pain is generally made 
worse by physical activity. Up to one-third of people have an aura, typically a short 
period of visual disturbance which signals that the headache will soon occur. 
Figure No.3 : Difference between head ache and Migraine. 
 
 
SIGNS AND SYMPTOMS: 
Migraines typically present with self-limited, recurrent severe headache 
associated with autonomic symptoms. About 15–30% of people with migraines 
experience migraines with an aura and those who have migraines with aura also 
frequently have migraines without aura. The severity of the pain, duration of the 
headache, and frequency of attacks are variable. A migraine lasting longer than 72 
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hours is termed status migrainosus. There are four possible phases to a migraine, 
although not all the phases are necessarily experienced: 
• The prodrome, which occurs hours or days before the headache 
• The aura, which immediately precedes the headache 
• The pain phase, also known as headache phase 
• The postdrome, the effects experienced following the end of a migraine attack 
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TREATMENTS AND DRUGS 
Although a number of medications have been used for the prevention of 
migraines, the medications that have been shown to be effective in controlled 
clinical trials, and are therefore recommended by the American Headache Society 
and the American Academy of Neurology (AAN) migraine prevention guidelines 
include: 
• Divalproex sodium/sodium valproate 
• Topiramate  
• Metoprolol  
• Propranolol  
• Timolol  
• Sumatriptan Succinate  
Other medications that are used to prevent migraine headaches include: 
ACE Inhibitors 
• Lisinopril  
Angiotensin II Receptor Antagonists (ARBS) 
• Candesartan  
Beta-blockers 
• Atenolol  
• Nadolol 
Calcium Channel Blockers 
• Diltiazem  
• Nimodipine  
• Verapamil  
Tricyclic Antidepressants 
• Amitriptyline  
• Nortriptyline 
• Imipramine 
• Doxepin  
• Protriptyline  
Other Antidepressants 
• Paroxetine  
• Fluoxetine  
• Sertraline  
Antiseizure Medications 
• Topiramate  
• Gabapentin  
• Divalproex sodium  
Herbals 
• Feverfew 
• Butterbur 
• Coenzyme Q10 
• Magnesium supplements 
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6. DRUG PROFILE-ESCITALOPARAM 
6.1. Description 
sumatriptan succinate, a selective 5-HT1B/1D receptor agonist. Sumatriptan 
succinate is chemically designated as 3-[2-(dimethylamino)ethyl]-N-methyl-indole5-
methanesulfonamide succinate (1:1),  
 
                                               Chemical Structure of sumatriptan succinate 
 
6.2. CHEMICAL DATA 
 Empirical formula  -  C14H21N3O2S 
 Molecular weight   - 295.401 g/mol 
 CAS Registry No.  - 103628-46-2 
 
6.2.1.  Systemic (IUPAC) Name: 
                      1-[3-[2-(dimethylamino)ethyl]-1H-indol-5-yl]-N-methyl methane 
sulfonamide 
6.3. Pharmacology: 
6.3.1 Indication 
              For the treatment of migraine attacks with or without aura. 
6.3.2. Pharmacodynamics 
Sumatriptan, an antimigraine drug, is a selective agonist of vascular serotonin ((5-
hydroxytryptamine; 5-HT) type 1-like receptors, likely the 5-HT1D and 5-HT1B 
subtypes. It has no significant affinity (as measured using standard radioligand binding 
assays) or pharmacological activity at 5-HT2, 5-HT3 receptor subtypes or at alpha1-, 
alpha2-, or beta-adrenergic; dopamine1; dopamine2; muscarinic; or benzodiazepine 
receptors.  
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6.3.3. Mechanism of action 
The 5-HT1B and 5-HT1D receptors function as autoreceptors, which inhibit the 
firing of serotonin neurons and a reduction in the synthesis and release of serotonin upon 
activation. After sumatriptan binds to these receptors, adenylate cyclase activity is 
inhibited via regulatory G proteins, incrases intracellular calcium, and affects other 
intracellular events. This results in vasoconstriction and inhibtion of sensory nociceptive 
(trigeminal) nerve firing and vasoactive neuropeptide release.  
6.3.4. Pharmacokinetic Parameters: 
 Bio-availability – 15% 
 Half life – 2.5  hours 
 Metabolism – Hepatic. In vitro studies with human microsomes suggest that 
sumatriptan is metabolized by monoamine oxidase (MAO), predominantly the A 
isoenzyme. 
 Protein binding- 14-21% 
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                                   7. EXCIPIENTS PROFILE 
                                          7.1. Cellulose, Microcrystalline 
Nonproprietary Names 
 BP: Microcrystalline Cellulose  
JP: Microcrystalline Cellulose 
PhEur: Cellulose, Microcrystalline 
USP-NF: Microcrystalline Cellulose 
 
Synonyms: Avicel PH 
 
Chemical Name and CAS Registry Number: Cellulose [9004-34-6] 
 
Empirical Formula and Molecular Weight: 
(C6H10O5)n≈36 000 
where n ≈ 220. 
 
Structural Formula 
 
Functional Category 
             Adsorbent, suspending agent, tablet 
and capsule diluents, tablet disintegrant. 
 
Description 
 Microcrystalline cellulose is purified, partially depolymerized cellulose that 
occurs as a white, odorless, tasteless, crystalline powder composed of porous particles. It 
is commercially available in different particle sizes and moisture grades that have 
different properties and application. 
The different commercial grades are available based on particle size distribution 
(µm) 
 
Solubility: 
  Slightly soluble in 5% w/v sodium hydroxide solution, practically insoluble in 
water, dilute acids, and most organic solvents. They partly dissolve in dilute alkali and 
swell in it. 
Table No 3: Uses of microcrystalline cellulose 
Uses Concentration % 
Adsorbent 
Antiadherent 
Capsule binder/diluents 
Tablet disintegrant 
Tablet binder/diluents 
20-90 
5-20 
20-90 
5-15 
20-90 
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7.2. Croscarmellose Sodium 
Nonproprietary Names 
BP: Croscarmellose Sodium 
JP: Croscarmellose Sodium 
PhEur: Croscarmellose Sodium 
USP-NF: Croscarmellose Sodium 
Synonyms: Ac-Di-Sol, crosslinked carboxy methyl cellulose sodium, Explocel, modified 
cellulose gum, Nymcel, ZSX Pharmacel XL, Primellose, Solutab, Vivasol. 
Chemical Name and CAS Registry Number:  
Cellulose, carboxymethyl ether, sodium salt, crosslinked 
[74811-65-7]  
Empirical Formula and Molecular Weight :  
The USP 32 describes carboxymethylcellulose sodium as the 
sodium salt of a polycarboxymethyl ether of cellulose. 
 
Structural Formula 
 
 
Functional Category: Tablet and capsule disintegrant. 
 
Description: Croscarmellose sodium occurs as an odorless, white or grayish white 
powder. 
Solubility 
Insoluble in water, croscarmellose sodium rapidly swells to 4–8 times its original 
volume on contact with water. Practically insoluble in acetone, ethanol and toluene. 
Applications in Pharmaceutical Formulation or Technology 
• Croscarmellose sodium is used in oral pharmaceutical formulations as a 
disintegrant for capsules, tablets, and granules.  
• In tablet formulations, croscarmellose sodium may be used in both direct-
compression and wet-granulation processes.  
• Croscarmellose sodium at concentrations up to 5% w/w may be used as a tablet 
disintegrant, although normally 2% w/w is used in tablets prepared by direct 
compression and 3% w/w in tablets prepared by a wet-granulation process. 
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7.3. Sodium Starch Glycolate 
Nonproprietary Names 
BP: Sodium Starch Glycolate 
PhEur: Sodium Starch Glycolate 
USP-NF: Sodium Starch Glycolate 
Synonyms: Carboxymethyl starch, sodium salt, carboxymethylamylum natricum, 
Explosol,  Explotab, starch carboxymethyl ether, sodium salt, Tablo,Vivastar P. 
Chemical Name and CAS Registry Number:  
Sodium carboxymethyl starch [9063-38-1] 
Empirical Formula and Molecular Weight :  
The molecular weight is typically 5X105–1106. 
 
Structural Formula 
 
 
Functional Category: Tablet and capsule disintegrant. 
 
Description: Sodium starch glycolate is a white or almost white free-flowing very 
hygroscopic powder. When examined under a microscope it is seen to consist of 
granules, irregularly shaped, ovoid or pear-shaped, 30–100 mm in size, or rounded, 10–
35 mm in size, compound granules consisting of 2–4 components occur occasionally. The 
granules show considerable swelling in contact with water. 
Solubility 
In water, sodium starch glycolate swells to up to 300 times its volume. 
Applications in Pharmaceutical Formulation or Technology 
• Sodium starch glycolate is widely used in oral pharmaceuticals as a disintegrant in 
capsuleand tablet formulations.  
• It is commonly used in tablets prepared by either direct-compression or wet-
granulation processes.  
• The usual concentration employed in a formulation is between 2% and 8%, with 
the optimum concentration about 4%, although in many cases 2% is sufficient.  
• Disintegration occurs by rapid uptake of water followed by rapid and enormous 
swelling. Although the effectiveness of many disintegrants is affected by the 
presence of hydrophobic excipients such as lubricants.  
• Increasing the tablet compression pressure also appears to have no effect on 
disintegration time.  
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7.5. Mannitol 
Nonproprietary Names 
                              BP           :        Mannitol 
                              JP            :        D-Mannitol 
                              PhEur      :        Mannitol 
                              USP         :        Mannitol 
 
Synonyms: Cordycepic acid, C Pharm Mannidex, E421, Emprove, manna sugar. 
 
Chemical Name and CAS Registry Number:   D-Mannitol [69-65-8] 
 
Empirical Formula and Molecular Weight:  C6H14O6 and 182.17 
 
Structural Formula 
 
 
Functional Category 
Diluent, plasticizer, sweetening agent, tablet and capsule diluents, 
therapeutic agent, tonicity agent. 
 
Description 
Mannitol is D-mannitol. It is a hexahydric alcohol related to mannose and 
isomeric with sorbitol. Mannitol occurs as a white, odorless, crystalline powder, or free 
flowing granules. It has a sweet taste, approximately as sweet as glucose and half as 
sweet as sucrose, and imparts a cooling sensation in the mouth. Microscopically, it 
appears as orthorhombic needles when crystallized from alcohol. Mannitol shows 
polymorphism. 
 
Applications in Pharmaceutical Formulation or Technology 
• Mannitol is widely used in pharmaceutical formulations and food products. In 
pharmaceutical preparations it is primarily used as a diluent (10–90% w/w) in 
tablet formulations. 
• Mannitol may be used in direct-compression tablet applications for which the 
granular and spray-dried forms are available. 
• Mannitol is commonly used as an excipient in the manufacture of chewable tablet. 
 
• In lyophilized preparations, mannitol (20–90% w/w) has been included as a 
carrier to produce a stiff, homogeneous cake that improves the appearance of the 
lyophilized plug in a vial. A pyrogen-free form is available specifically for this 
use. 
 
• Mannitol has also been used to prevent thickening in aqueous antacid suspensions 
of aluminum hydroxide (<7% w/v). 
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7.6. Magnesium Stearate 
 
Nonproprietary Names 
BP: Magnesium Stearate 
JP: Magnesium Stearate 
PhEur: Magnesium Stearate 
USP-NF: Magnesium Stearate 
 
Synonyms: Dibasic magnesium stearate, magnesium distearate, magnesia  stearas. 
 
Chemical Name and CAS Registry Number: Octa decanoic acid magnesium salt and 
[557-04-0] 
 
Empirical Formula and Molecular Weight:  C36H70MgO4 and591.24 
 
Structural Formula: [CH3(CH2)16COO]2Mg 
 
 
 
Functional Category: Tablet and capsule lubricant 
 
Description 
Magnesium stearate as a compound of magnesium with a mixture of solid organic 
acids that consists chiefly of variable proportions of magnesium stearate and magnesium 
palmitate. (C32H62MgO4). 
Magnesium stearate is a very fine, light white, precipitated or milled, impalpable 
powder of low bulk density, having a faint odor of stearic acid and a characteristic taste. 
The powder is greasy to the touch and readily adheres to the skin. 
 
Applications in Pharmaceutical Formulation or Technology 
Magnesium stearate is widely used in cosmetics, foods, and pharmaceutical 
formulations. It is primarily used as a lubricant in capsule and tablet manufacture at 
concentrations between 0.25% and 5.0% w/w. It is also used in barrier creams. 
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7.7. Aspartame 
 
Nonproprietary Names 
BP: Aspartame 
PhEur: Aspartame 
USP-NF: Aspartame 
Synonyms: 3-amino-N-(a-methoxycarbonylphenethyl)-succinamic acid, APM, 
aspartamum, aspartyl phenylamine methyl ester, Canderel, E951, Equal, methyl N-L-a-
aspartyl-L-phenylalaninate, NatraTaste,  NutraSweet, Pal Sweet, Pal Sweet Diet. 
 
Chemical Name and CAS Registry Number: N-L-a-Aspartyl-L-phenylalanine 1-
methyl ester [22839-47-0] 
Empirical Formula and Molecular Weight:  C14H18N2O5  294.30 
 
Structural Formula:  
 
 
 
Functional Category: Sweetening agent. 
 
Description: Aspartame occurs as an off white, almost odorless crystalline powder with 
an intensely sweet taste. 
Applications in Pharmaceutical Formulation or Technology 
Aspartame is used as an intense sweetening agent in beverage products, food 
products, and table-top sweeteners, and in pharmaceutical preparations including tablets, 
powder mixes, and vitamin preparations. It enhances flavor systems and can be used to 
mask some unpleasant taste characteristics. The approximate sweetening power is 180–
200 times that of sucrose. 
Unlike some other intense sweeteners, aspartame is metabolized in the body and 
consequently has some nutritive value: 1 g provides approximately 17 kJ (4 kcal).  
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  8. MATERIALS AND EQUIPEMENTS  
 8.1. MATERIALS USED: 
Table No 4: Materials Used 
S.No Materials Suppliers / Manufacturer 
1 Sumatriptan Succinate Sooriyan Pharmaceuticals, Chennai. 
2 Microcrystalline Cellulose PH 102 (Avicel 102) Accent Microcel Industries 
3 Polyplasdone XL (Crospovidone XL) ISP Technologies Inc 
4 Sodium starch glycolate Nice 
5 Magnesium stearate Nithika Chemicals 
6 Pearlitol -100SD (Mannitol SD-200) RoquettesFre`res 
7 Aspartamate Lobachem 
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8.2.  INSTRUMENTS USED 
Table No 5: Instruments Used 
S.No Equipment Manufacturer 
 
1 Digital Balance Wensar PGB - 300 
2 Sieves Indicot (India) 
3 Tapped Density Tester Electrolab 
4 Mechanical Stirrer Remi Motors  Bombay 
5 UV-Visible Spectrophotometer LAB INDIA UV 3000+ 
6 Dissolution Test Apparatus 
Labindia Analytical 
Instruments Pvt Ltd. 
Mumbai , Model-DISSO 
2000 
7 Temperature controller(hot air oven) GABAKS 
8 FTIR BRUKER HTS-XT 
9 Compression machine Cadmach 
10 Vernier Calipers Mitutoyo 
11 Disintegration Test Apparatus,USP ROLEX 
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9. PREFORMULATION 
  
Preformulation testing is first step in the rational development of dosage forms of 
a drug substance. It can be defined as – “ as investigation of physical and chemical 
properties of a drug substance alone and when combined with excipients”. The overall 
objective of preformulation testing is to generate information useful to the formulation in 
developing stable and bioavailable dosage forms that can be mass produced.  The 
preformulation should start at the point after biological screening, when a decision is 
made for further development of compound in clinical trials.  The preformulationstudies 
should consider the following before going through the formal program which includes: 
• Available physicochemical data (including chemical structure and different salts 
available). 
• Anticipated dose 
• Supply situation and development schedule. 
• Availability of stability , assay. 
• Nature of information the formulator should have or would like to have. 
The following preformulation studies were performed for the obtained sample of 
drug.   
9.1. Organoleptic properties 
9.1.1. Color and nature 
Transferred small quantity of the sample on a white piece of paper, spreaded the 
powder and examined visually. 
Escitalopram  white fine powder. 
9.1.2. Taste and odour 
Very less quantity of Escitalopram was used to get taste with the help of tongue as 
well as smelled to get the odor 
 9.1.3. Particle Size , Shape and Surface Area 
Various physical and chemical properties of drug substances are affected by their 
particle  size distribution and shapes. Size also plays a role  inthe homogeneity of final 
tablet.  When large differences in size exist between the API and excipientsm mutual 
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sieving (demixing) effects can occur making through mixing difficult on, it attained, 
difficult to maintain during the subsequent processing steps. 
If the material become too fine, then undesirable properties such as electrostatin 
force effects and other surface active properties causing undue stickiness and lack of 
flowability manifest.  It is probably safest to grind most drugs having particles that are 
approx 100µm in diameter. 
 
                  Table No:  7. General Techniques For Determining Particle Size 
Techniques Particle size( µm) 
Microscopic 1-100 
Sieve >50 
Sedimentation >1 
Eutriation 1-50 
Centrifugal <50 
Permeability >1 
Light Scattering 0.5-50 
9.2. Physical characteristics: 
9.2.1. Flow properties:  
  The flow properties of powders are critical for an efficient tableting 
operation.  A good flow of powder or granulation to be compressed is necessary to assure 
efficient missing and acceptable weight uniformity for the compressed tablets.  If a drug 
is identified at the pre formulation stage to be “poorly flowable”, the problem can be 
solved by selecting appropriate excipients.  In some cases, drug powders may have to be 
pre-compressed or granulated to improve their flow properties.  During pre formulation 
evaluation of drug substance, therefore, its flowability characteristic should be studied, 
especially when the anticipated dose of the drug is large. 
9.2.2. Angle of Repose: 
Angle of repose is defined as the maximum angle possible between the surface of 
a pile of the powder and the horizontal plane. 
 
 
CHAPTER-9                                                             PREFORMULATION 
 
J.K.K.NATTRAJA COLLEGE OF PHARMACY Page 39 
 
Procedure:  
 A funnel was kept vertically in a stand at a specified height above a graph paper 
placed on a horizontal surface.  The funnel bottom is closed and 10 gm of sample powder 
is filled in funnel.  Then funnel was opened to release the powder on the paper to form a 
smooth conical heap, is found by measuring in different direction.  The height of the heap 
was measured by using scale.  The values of angle of repose are calculated by using the 
following formula: 
tanθ = h/r 
 
 
Where,  θ – angle of repose 
h- Height of the heap  
 r - Radius of the heap  
 
              Table No: 6. Angle of repose limits. 
Angel of repose Flowability 
<25 Excellent 
25-30 Good 
30-40 Passable 
>40 Very poor 
The results shown in results and discussion. 
9.2.3. Bulk density 
 Bulk density is the ratio of mass of powder to the bulk volume. Bulk density 
largely depends on particle shape, as the particles become more spherical in shape, bulk 
density is increase. In addition as granules size increase, bulk density decrease. 
 Bulk density is determined by measuring the volume of a known mass of powder 
sample that has been passed through a screen into a graduated cylinder. 
Procedure: 
 A known quantity of powder was poured into the measuring cylinder carefully 
level the powder with out compacting, if necessary and read the unsettled apparent 
volume. Calculate the bulk density, in gm per ml, by the formula 
θ = tan -1 (h/r) 
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                                             (ρb) = m / Vb. 
Where,  ρb =Bulk Density  
  m = mass of powder 
  Vb = initial / bulk volume 
The results shown in results and discussion 
 Tapped density: 
 Tapped density is the ratio of mass of powder to the tapped volume. 
Procedure: 
 A quantity of 5g of the powder (W) from each formula was introduced into a 
25 ml measuring cylinder. After the initial volume was observed, the cylinder was 
allowed to fall under its own weight onto a hard surface from the height of 2.5 cm at 
2 sec intervals. The tapping was continued until no further change in volume was 
noted. Calculate the tapped density, in gm per ml, by the formula: 
(ρt)= m/Vt 
Where,  ρt =Tapped Density 
  m = mass of powder 
  Vt= final / tapped volume 
9.2.4. Measurement of Powder Compressibility:  
 The compressibility Index are measures of the propensity of a powder to be 
compressed. As such, they are measures of the relative importance of inter particulate 
interactions. In a free flowing powder, such interactions are generally less and tapped 
densities will be closer in value. For poorer flowing materials, there are frequently greater 
inter particle interactions, and a greater difference between bulk and tapped densities will 
be observed. These differences are reflected in the compressibility Index Calculated by 
the formula, 
            Tapped density - Initial bulk density 
% Compressibility   =   ————————————————— x 100 
      (Carr’s index)                             Tapped density    
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Table No: 7. Flow properties and corresponding Carr’s Index values 
 
Excellent <10 
Good 11 – 15 
Fair 16 – 20 
Possible 21 – 25 
Poor 26 – 31 
Very poor 32 – 37 
Very very poor >38 
The results are shown in results and discussion 
9.2.5. Hausner Ratio: 
 It is the ratio of volume of tapped volume or tapped density to bulk density. 
 Hausner Ratio =  Vb/Vt or ρt /ρb. 
 
Table No: 8. Flow Properties and Corresponding Hausner’s ratio 
Excellent 1.00 – 1.11 
Good 1.1 – 1.18 
Fair 1.19 – 1.25 
Possible 1.26 -1.34 
Very poor 1.35 -1.45 
Very very poor >1.60 
 
9.2.6.  Melting point: 
It is one of the parameters to judge the purity of crude drugs.  In case of pure chemicals, 
melting points are very sharp and constant.   
Procedure: 
 A small quantity of powder was placed into a fusion tube.  That tube is placed in 
the melting point apparatus containing castor oil.  The temperature of the castor oil was 
gradual increased automatically and read the temperature at which powder started to melt 
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and the temperature when all the powder gets melted. The results shown in results and 
discussion. 
9.2.7. Solution properties: 
9.2.7 a) pH of the solution 
 Weighed and transferred accurately about 1.0 g of sample in a 200 ml clean and 
dried beaker, dissolved in carbon dioxide free water and made up the volume to 100 ml 
with same solvent, mixed. Read the pH of freshly prepared solution by using 
precalibrated  pH meter. The results are shown in table.8. 
 9.2.7 b) Solubility: 
A semi quantitative determination of the solubility was made by adding solvent in 
small incremental amount to a test tube containing fixed quantity of solute or vice versa.  
After each addition, the system is vigorously shaken and examined visually for any 
undissolved solute particles.   The solubility are expressed in terms of ratio of solute and 
solvent. The results are shown in table.9. 
 
9.2.8  Identification of drug and compatibility study: 
9.2.8 a) Identification of drug By FT-IR: 
  The drug can be identified by using FT-IR. 
9.2.8 b) By Physical observation 
It was determined as per procedure given in method section. The following table 
illustrated the result. 
Table No:9. Physical Compatibility Studies 
Test Observations Inference 
Physical 
compatibility 
No change of color 
These materials are compatible for 
formulations. 
 
9.2.8 c) Procedure By FT-IR Studies 
The IR spectrums of the Sumatriptan Succinate with exipients were taken by preparing 
dispersion in dry potassium bromide under dry condition. Superimposed these spectra. 
The transmission minima (absorption maxima) in the spectra obtained with the sample 
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corresponded in position and relative size to those in the spectrum obtained with the 
standards. 
 
9.3. UV SPECTROSCOPIC METHOD FOR ANALYSIS OF SUMATRIPTAN 
SUCCINATE 
9.3.1. CALIBRATION CURVE OF SUMATRIPTAN SUCCINATE: 
Measured the absorbance of the above prepared standard solutions at 226 nm. 
Plotted a graph of concentration (in µg/ml) on X axis and absorbance (in nm) on Y axis  
TableNo: 10. Caliberation curve for Sumatriptan Succinate 
S. No. Concentration (µg/ml) Absorbance (nm) 
1 0 0 
2 2 0.226 
3 4 0.386 
4 6 0.581 
5 8 0.768 
6 10 0.958 
Slope 0.0247 
R2 0.9992 
Figure No: 5 : Caliberation Curve of Sumatriptan Succinate 
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10. FORMULATION AND DEVELOPMENT OF SUMATRIPTAN 
SUCCINATE  IMMEDIATE RELEASE TABLETS 
Table No: 11. FORMULATION 
INGREDIENTS(in mg) 
FORMULATION BATCHES 
F1 F2 F3 F4 F5 F6 F7 F8 
Sumatriptan Succinate 25 25 25 25 25 25 25 25 
MCC PH 102  (Avicel 102) 200 200 200 200 200 200 200 200 
Croscarmellose sodium (CCS) 3.5 7 9 12 0 0 0 0 
Sodium Starch Glycolate (SSG) 0 0 0 0 3.5 7 9 12 
Mannitol 112.5 109 107 104 112.5 109 107 104 
Magnesium Stearate 2 2 2 2 2 2 2 2 
Aspartamate 7 7 7 7 7 7 7 7 
Average Weight 350 350 350 350 350 350 350 350 
Procedure: 
  All the ingredients were weighed and mixed well. Then it is tableted by direct 
compression method - proton Mini Press  
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11. EVALUATION 
11.1. PRE-COMPRESSION PARAMETERS: 
A) Angle of repose: 
      Angle of repose is defined as the maximum angle possible between the surface of 
a pile of the powder and the horizontal plane. 
5 grams of the sample was taken in a funnel fixed in a holder (6 cm) above the 
surface at an appropriate height and a graph of sheet was placed below the funnel. The 
sample was passed through the funnel slowly. The height of the powder heap formed was 
measured. The circumference of the heap formed was drawn with a pencil on the graph 
paper. The radius was measured and the angle of repose was determined using the above 
formula. This was repeated five times for a sample. 
Table No: 12. Flow properties and corresponding Angle of Repose 
Flow property Angle of Repose (Degree) 
Excellent 25-30 
Good 31-35 
Fair-aid not needed 36-40 
Passable- may hang up 41-45 
Poor- must agitate, vibrate 46-55 
Very poor 56-65 
Very, very poor > 66 
 
 
 
Where, 
h = height, 
r = radius, 
θ = Angle of repose. 
The results are given in results and discussion. 
B) Determination of bulk density and tapped density: 
A quantity of 5g of the powder (W) from each formula was introduced into a 25 
ml measuring cylinder. After the initial volume was observed, the cylinder was allowed 
θ = tan -1 (h/r) 
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to fall under its own weight onto a hard surface from the height of 2.5 cm at 2 sec 
intervals. The tapping was continued until no further change in volume was noted. The 
bulk density, and tapped density were calculated using the following formulas  
 
 
Where, 
 m = mass of the powder, 
Vb = initial or bulk volume, 
Vt = final or tapped volume. 
 The results are shown in results and discussion. 
C)Measurement of  Hausner ratio and Carr’s Index 
C1).Hausner’s Ration: 
          Hausner’s ratio indicates the flow properties of powder and measured by the 
ratio of tapped density to bulk density. Hausner’s ratio was determined by the given 
formula: 
Hausner Ratio = Vb/Vt 
Where, 
Vb = initial or bulk volume 
Vt = final or tapped volume 
The results are shown in results and discussion.  
Table No: 13. Scale of flowability 
Compressibility index (%) Flow character Hausner Ratio 
≤ 10 Excellent 1.10-1.11 
11-15 Good 1.12-1.18 
16-20 Fair 1.19-1.25 
21-25 Passable 1.26-1.34 
26-31 Poor 1.35-1.45 
32-37 Very poor 1.46-1.59 
>38 Very, very poor >1.60 
 
 
Bulk density(ρb)= m / Vb 
  Tapped density(ρt)= m/Vt 
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C2).Carr’s Index/Compressibility Index:  
 Compressibility is the ability of powder to decrease in volume under pressure 
using bulk density and tapped density the percentage compressibility of powder were 
determined, which is given as carr’s compressibility index. It is indirectly related to the 
relative flow rate. Carr’s compressibility index was determined by the given formula 
                               Tapped density - Initial bulk density 
% Compressibility   =   ————————————————— x 100 
                    (Carr’s index)                             Tapped density 
 
The results shown in results and discussion. 
 
11.2.EVALUATION OF  SUMATRIPTAN SUCCINATE : 
A)Weight Variation Test: 
  The tablet of one particular batch should have uniformity in weight.  If any 
weight variation is found, it should fall within the prescribed limits. According to USP 
maximum % deviation allowed are as follows :- 
                                            Table No: 14.Weight Variation Test. 
Average weight of tablets(mg) Maximum % difference allowed 
130mg or less ±10% 
130-324mg ±7.5% 
Above 324mg ±5% 
 
  A sample of 20 tablets isselected randomly from a particular batch and 
weighed individually and collectively. The average weight of the tablets is calculated. 
The individual weights are then compared with average weight. The weights of not more 
than two of the tablets should not differ and calculate the average weight by more than 
the prescribed limit and no tablet should differ by more than the double the limits.  
                                                              Tablet weight-Average weight 
% Deviation   =   ————————————————— x 100 
                     Tablet weight 
The results shown in results and discussion 
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B) Friability Test: 
20 tablets were weighed and subjected to rotate on friability test apparatus. The 
drum rotated at a speed of 25 rpm for 4 minutes, then dedusted and reweighed the tablets. 
Percentage friability was calculated by the following formula.  
 
 
Where, 
 Wo = Initial weight,  
  W   = Final weight.  
Percentage friability of tablets less than 1% is considered acceptable. The results shown 
in results and discussion. 
 
C) Hardness Test: 
 Hardness of a tablet determines its tensile strength.  It must be such that the 
tablets withstand the shock of handling, packing, and shipping.  It is measured in terms of 
load/pressure required to crush it when placed on its edge.  Generally, two types of 
hardness testers are used to determine the hardness. 
C1) Monsanto Hardness Tester: 
  It consists of a barrel containing a compressible spring held between two 
plungers.  The spring can be compressed by moving the knob forward.  The tablet to be 
tested held between a fixed and moving plunger and reading of the indicator is adjusted 
to zero.  The force applied to the edge of the tablet is gradually increased by moving the 
screw know forward until the breaks. The reading is noted from the scale which indicates 
the pressure required in kg or lb/cm2to break the tablet.  Hardness of 4kg/cm2 is 
considered to be minimum requirement. 
C2) Pfizer Tablet Hardness Tester: 
 This is slightly improved instrument used for determing the hardness of tablet.  It 
works on the principle of plier.  Pressure gauze is fitted on one arm of the tester.  The 
tablet to be tested is put vertically in between the jaws which are pressed with hand until 
the tablet breaks.  The reading can be noted from the indicator of the pressure gauze in 
terms of kg or lbs. 
Percentage of Friability (%F)=100 (1-w/w0) 
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 The hardness of  a sample batch of Escitaloparam  tablets was carried out by 
using Monsanto type hardness tester. The hardness of the tablet kg / cm² was measured.  
The results are shown in results and discussion. 
D) Thickness Test:  
Control of physical dimension of the tablets such as sizes and thickness is 
essential for consumer acceptance and to maintain tablet to tablet uniformity.  
Manufacturers set the limits on the thickness of the tablets of their products in order to 
avoid any problems during automatic counting and packing. If the thickness of the tablet 
goes beyond a certain limit, it may block the channels of the machines. Hence there 
should be in-process control to maintain the thickness of the tablets.  The dimensional 
specifications were measured using vernier calipers.  
Six tablets from each batch were tested and average values were calculated.The 
thickness of the tablet is mostly related to the tablet hardness can be uses as initial control 
parameter. 
 The results are shown in results and discussion.  
D1)  Diameter and Shape:   
           The diameter and shape of the tablets are determined by the dies and punches used 
for the compression.  Less concave the punches, the more flat will be the tablets.  
Conversely, the more concave the punches, more convex would be the resulting tablets.  
Similarly, punches having raised impressions will produce recessed impressions on the 
tablets.  Whereas punches having recessed impression, will produce raised impressions 
on the tablet surface.  Therefore, proper selection of punches and dies should be done so 
as to produce tablets will desired diameter and shape. 
D2) Drug content: 
Weigh and powdered 10 tablets in a mortar. From this powder equivalent to 
100mg of Sumatriptan Succinate  was taken in a 100ml volumetric flask to this water was 
added and then the solution was subjected to sonication for about 10min’s for complete 
solubilization of drug and the solution was made up to the mark with water filtered the 
drug content was estimated by measuring the absorbance at 244 nm by using UV-Visible 
spectrophotometer. 
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E) Disintegration Time: 
The test is performed invitro to determine the time in which a tablet disintegrates 
in the water at the 37±2°C. The apparatus which is used to simulate all the conditions of 
mouth, for the determination of disintegration time is called as Disintegration Time. 
It consist of two hot plates with housing for beakers, thermostatically controlled 
heaters to maintain the temperature, two baskets each having provision for fixing 6 glass 
or plastic tubes provided with guided discs and stainless wire mesh.  Each unit is suitable 
for performing two tests at a time. 
The glass or plastic tubes are open at one end and fitted with sieve No. 10 mesh at 
the other end. The tubes are suspended in bath containing water or suitable liquid which 
is maintained through a distance of 75mm, the volume of the liquid and the distance of 
movement is adjusted in such a way that the highest point, the sieve should break the 
surface of the liquid.  
six tablets are placed in each of the six tubes along with a guided plastic disc over 
the tablets tube and the assembly was suspended into the 1000ml beaker containing 
Water maintained at 37±2°C and operated the apparatus for 15 minutes. The tubes are 
allowed to move up and down as per the specification discussed above and the 
disintegration time is noted when all the tablets particles have passed through the sieve.  
The disintegration time should comply with official time unless otherwise in the 
monographs. The assembly was removed from the liquid and the tablets were observed. 
If one or two tablets fail to disintegrate completely, repeat the test on 12 additional 
tablets. The requirement is met if not less than 16 of the total of 18 tablets tested are 
disintegrated. 
E) Wetting time and water absorption ratio:  
Wetting time of dosage form is related to with the contact angle. Lower wetting 
time implies a quicker disintegration of the tablet. 
E1) Wetting time: 
It is closely related to the inner structure of the tablets and to the hydrophilicity of 
the excipients. To measure wetting time, five circular tissue papers of 10cm diameter are 
placed in a petridish with a 10cm diameter. 10ml of water containing eosin, a water 
soluble dye, is added to petridish. A tablet is carefully placed on the surface of the tissue 
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paper. The time required for water to reach upper surface of the tablet is noted as a 
wetting time. 
E2) Water absorption ratio:   
A piece of tissue paper folded twice was placed in a small Petri dish containing 6 ml 
of water. A tablet was put on the paper & the time required for complete wetting was 
measured. The wetted tablet was then weighed. The water absorption ratio, R can be the 
determined according to the following equation; 
R = 100 (Wa-Wb) / Wb 
Where,  
Wb; The weight of the tablet before keeping in the petridish. 
Wa; The wetted tablet from the petridish is taken and reweighed. 
F)  Dissolution: 
F1) Dissolution Rate: 
Dissolution rate is defined as the amount of solute dissolved in a given solvent per unit 
time under standard conditions of temperature, pH, solvent composition and constant 
solid surface area. The developed dissolution test can serve also a routine control 
mechanism to assure the proper dissolution characteristics, as well as the uniformity of 
regular production. 
F2) Measurement of the Intrinsic Dissolution Rate: 
• This measurement is extremely important input factor during the initial drug 
screening and formulation development programs. 
• Measurement over the entire physiological pH range can be very useful in predicting 
whether the absorption of moderately or poorly soluble drugs is dissolution rate 
limited. 
• Such information is essential in order to develop a suitable dosage form that is free 
from bioavailability problems. 
• The information also is very useful for improving existing formulations that have 
demonstrated bioavailability problems. 
• It is important to point out while the intrinsic dissolution rate data is very useful in 
characterizing the solubility behavior of drug substance, it is of little value in 
describing the characteristics of the pharmaceutical forms. 
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F3)  Dissolution Apparatus of Immediate Release Sumatriptan Succinate  tablets: 
invitro dissolution of  Sumatriptan Succinate  was studied in USP dissolution 
apparatus (Electrolab) employing a Basket stirrer. 900 ml Water was used as dissolution 
medium at 50 rpm. The temperature of 37 ± 0.5 °C was maintained throughout the 
experiment. Complex equivalent to mg of Sumatriptan Succinate  was used in each test. 5 
ml of sample of dissolution medium were withdrawn by means of syringe fitted with pre-
filter at known intervals of time and analyzed for drug release by measuring the 
absorbance at 226 nm after suitable dilution with 6.8 pH phosphate buffer. The volume 
withdrawn at each time interval was replaced with fresh quantity of dissolution medium. 
The amount of Sumatriptan Succinate  released was calculated and plotted against time 
and compared with marketed drug was studied. 
F4) Dissolution Study 
In-vitro release profile: 
 Medium    : Water 900ml. 
 Apparatus : USP II (Paddle) 
 Speed        : 50 rpm 
 Time        : 45 minutes 
 Temperature  : 37 0C ± 0.5 0C 
 λ Max   : 226 nm  
 
Perform the test on six tablets place one tablet in each dissolution vessel containing 900 
ml of Water maintained at 37 0C ± 0.5 0C. At specified time withdrawn required amount 
of sample and replace the same amount with (maintain sink condition), then absorbance 
was taken and calculate percentage release.  
               Absorbance X 900 X Dilution 
% Purity   =   ————————————— x 100 
              Slope X 1000 X label claim 
The results are given in results & discussion. 
G) Stability studies: 
 The optimized tablets were packed in amber-colored bottle, which was tightly 
plugged with cotton and capped. It was then stored at 40°C / 75% RH for 8 weeks. The 
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tablets were evaluated for hardness, drug content and dissolution study and compared 
with tablets evaluated immediately after manufacturing. 
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12. RESULT AND DISCUSSION 
12.1.Pre formulation Studies: 
Organoleptic properties: 
 These tests were performed as per procedure. The results are illustrated in following 
table.  
Table No. 15:  Organoleptic Properties 
Test Specification / limits Observations 
Color  White color white powder 
Odour Odourless Odourless 
The result complies as per specification. 
Angle of repose : 
 It was determined as per procedure given in material and method part. The results are, 
Table No.16: Flow properties  
Material Angle of repose 
Sumatriptan Succinate   36o.17” 
The result shows that drug having poor flow. 
Bulk density and tapped density: 
 It was determined as per procedure given in material and method part. The results are, 
                                                               Table No.17: Density 
Material Bulk Density (gm/ml) Tapped density (gm/ml) 
Sumatriptan Succinate   0.26 0.22 
Powder compressibility: 
 It was determined as per procedure given in material and method part. The results are, 
Table No.18: Powder Compressibility  
 
 
 
Melting point: 
 It was determined as per procedure given in material and method part. The results are, 
 
 
Materials Compressibility index Hausner ratio 
Sumatriptan Succinate   31.45% 1.24 
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Table No. 19: Melting point 
Material Melting point range Result 
Sumatriptan Succinate   169-171 °C Complies 
The result indicates that the Sumatriptan Succinate  drug was pure one.  
SOLUTION PROPERTIES: 
pH of the solutions 
 pH of the solution was determined as per procedure given in material and method part.  
Table No.20:  pH 
 Material Test  Specification  Observation  
Sumatriptan 
Succinate   
pH 8.90 8.85 
The result complies as per specification 
Solubility: 
 It was determined as per procedure given in 9.4.2 in material and method part. The 
following table 17 illustrated the result. 
Table No.21: Solubility 
Test Specification Result 
Solubility 
Freely soluble in Water, DMSO, insoluble in 
 Ethanol. 
Complies 
The result complies as per specification. 
Drug - Excipient Compatibility Studies 
A) Physical Observation: 
There are no such changes in the physical observation after mixing of ingredients. 
B) Drug Identification by FTIR: 
The graph is compared with the standard FTIR graph given in pharmacopoeia or 
prescribed standards and confirmed through the corresponding peaks. 
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Fig. No. 6 : FTIR Graph of Sumatriptan Succinate  
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Fig. No.7 : FTIR Graph Sumatriptan Succinate  + MCC 
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Fig. No.8 : FTIR Graph Sumatriptan Succinate  + CCS 
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Fig. No.9 : FTIR Graph Sumatriptan Succinate  + CCS 
 
 
CHAPTER- 12                                           RESULT AND DISCUSSION 
 
J.K.K.NATTRAJA COLEGE OF PHARMACY Page 60 
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PRECOMPRESSION PARAMETERS: 
Table. No. 23: EVALUATIONS OF GRANULES 
Batch. 
N0. 
Angle of 
Repose(0) 
Bulk 
Density(g/ml) 
Tapped bulk 
density(g/ml) 
Carr’s index 
(%) 
Hausner’s  
Ratio 
F1 27°46' 0.453 0.512 11.40 1.24 
F2 26°27' 0.489 0.532 11.81 1.29 
F3 27°32' 0.412 0.554 13.63 1.21 
F4 24°17' 0.409 0.512 14.96 1.26 
F5 24°.52' 0.467 0.568 12.13 1.19 
F6 24°.26' 0.449 0.587 11.12 1.11 
F7 25°.33' 0.456 0.501 11.33 1.23 
F8 27°.68' 0.467 0.569 12.28 1.22 
 
Discussion: 
The angle of repose for the formulated blend F1-F8 was found to be in the range 240.17' 
to 270.68' shows good flow property.  
Compressibility index for the formulations F1-F8 found between 11.12% to 14.96% 
indicating  the powder blend has the required flow property for compression.  
Hausner’s Ratio for the formulations F1-F8 found between 1.11 to 1.29 indicating  the 
powder blend has the required flow property for compression.  
 
 
 
 
 
 
 
 
CHAPTER- 12                                           RESULT AND DISCUSSION 
 
J.K.K.NATTRAJA COLEGE OF PHARMACY Page 62 
 
 
EVALUATION OF SUMATRIPTAN SUCCINATE  TABLETS: 
Table. No: 24.WEIGHT VARIATION AND FRIABILITY: 
Batch. 
No 
Weight Variation 
(%) 
Friability (%) 
F1 350±1.52 0.41 
F2 350±2.37 0.34 
F3 348±1.44 0.30 
F4 351±1.88 0.48 
F5 351±2.59 0.48 
F6 351±2.13 0.48 
F7 350±1.52 0.39 
F8 351±1.49 0.40 
 
Discussion:  
The weight variation of the tablet in the range of ± 1.49 % to ± 2.56 % ( below 5%) 
complying with pharmacopoeial specification. 
The friability of the tablet in the range of 0.30 % to 0.48% (below 1%) complying with 
pharmacopoeial specifications. 
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Table. No: 25. Thickness, Hardness and Disintegration Time: 
Batch. 
No 
Thickness 
(mm) 
Hardness 
(Kg/cm2) 
F1 2.12±0.2 2.13 
F2 2.02±0.2 2.61 
F3 2.23±0.1 2.12 
F4 2.12±0.1 2.34 
F5 2.23±0.1 2.69 
F6 2.10±0.1 2.79 
F7 2.05±0.2 2.51 
F8 2.08±0.3 2.59 
 
 
Discussion: 
The thickness of the formulations from F1- F8 was found to be in the range of 2.02±0.2 
to 2.23±0.2 and hardness of the formulated tablets was found to 2.13 to 2.79 indicating a 
satisfactory mechanical strength.  
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Table. No: 26. Wetting Time and Disintegration Time: 
Batch. 
No 
Wetting Time 
(Sec) 
DISINTEGRATION 
TIME (seconds) 
F1 130 135 
F2 104 108 
F3 76 80 
F4 63 66 
F5 118 122 
F6 81 84 
F7 53 56 
F8 45 48 
 
Discussion: 
The Wetting time of the formulations from F1- F12 was found to be in the range of                    
45-130 seconds. Lower wetting time implies a quicker disintegration of the tablet. F6 shows very 
lower wetting time it reflects in faster DT.  
Water absorption ration is around 63% shows for the formulation F8. 
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Table. No:27. CUMULATIVE % RELEASE OF SUMATRIPTAN SUCCINATE  Mouth 
Dissolving  
Tablets F1-F4 
 
Discussion: 
 From the invitro dissolution study of all formulations (F1-F8), formulation F8 release 
around 98% of drug at the end of 8 min’s for a immediate release tablets of Sumatriptan 
Succinate . Therefore the F8 formulation chosen as the best formulation from all 12 batches. 
 
  
Time (mts) 
% Drug Release of Formulations 
F1 F2 F3 F4 
0 0 0 0 0 
1 24.21 28.21 31.47 34.71 
2 40.39 46.45 50.39 54.07 
4 53.91 59.62 61.22 64.73 
6 66.26 68.71 71.46 78.38 
8 75.54 76.63 81.92 86.42 
10 89.19 85.22 89.75 92.53 
12 93.65 91.38 93.71 97.34 
15 96.78 98.76 99.27 99.81 
17 98.37 --- --- --- 
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Table. No:28. CUMULATIVE % RELEASE OF SUMATRIPTAN SUCCINATE  Mouth 
Dissolving Tablets F5-F8 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Time (mts) 
% Drug Release of Formulations 
F5 F6 F7 F8 
0 0 0 0 0 
1 22.13 30.12 34.23 40.41 
2 38.39 46.43 51.17 56.43 
4 53.12 64.64 69.17 76.73 
6 69.46 77.31 82.45 89.27 
8 82.31 89.37 90.90 98.14 
10 97.18 99.33 98.92 --- 
12 97.25 --- --- --- 
15 --- --- --- --- 
17 --- --- --- --- 
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Fig.No.10: Graph of Cumulative % Release of Sumatriptan Succinate  Mouth Dissolving  
Tablets F1-F4 
 
 
 
Fig.No.11: Graph of Cumulative % Release of Sumatriptan Succinate  Mouth Dissolving  
Tablets F5-F8 
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Fig.No.12: Graph: Cumulative % Release of Sumatriptan Succinate Mouth Dissolving  
Tablets F8 
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     13. SUMMARY AND CONCLUSION 
The present study involves formulation and evaluation of immediate release 
tablets of SUMATRIPTAN SUCCINATE. Endeavours with respect to Direct 
compression method used for formulating tablets was best suitable to achieve 100% 
results. 
Preformulation studies involving organo-leptic bulk density, angle of repose, 
tapped density, compressibility index, hausner ratio, melting point range, pH and 
solubility were carried out as per USP specifications. 
Polymers such as Croscarmellose Sodium (CCS), Sodium Starch Glycolate 
(SSG) were utilized in the trails. All the physical evaluations carried in 
preformulation studies were carried out on all the three different polymers utilized. 
All the formulations exhibited values within the acceptable range. 
Tablets were evaluated for weight variations, hardness, friability, thickness 
and Dissolution studies.  
 Release studies were carried out in Water, for 45 minutes. Evaluated samples 
for all the three polymer systems. Results indicated that formulation F8, gave 98.14% 
release within 8 minutes which is formulated with Sodium Starch Glycolate (SSG) 
alone. Assay was carried out for formulation F8 and was found to be 96.12%.  
 Remaining formulations gave fluctuating release profiles. The formulation F8 
was considered to be better among the trails accomplished. 
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